4SCAR-T Therapy Post CD19-targeted Immunotherapy

Recruiting now · Phase 1/Phase 2

Conditions studied: CD19 Negative B-cell Malignancies

In brief

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Key facts

Study ID

NCT04430530

Run by

Shenzhen Geno-Immune Medical Institute

People needed

100

Starts

2026-06-01

Expected to finish

2030-12-31

Last updated by the study team

2026-06-23

Who can join

Age: 1 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age older than 6 months.
• B cell malignancies relapsed after anti-CD19 immunotherapy.
• Malignant B cells expressing one or more of the following surface molecules: CD22/CD123/CD38/CD10/CD20.
• The KPS score over 80 points, and survival time is more than 1 month.
• Greater than Hgb 80 g/L.
• No contraindications to blood cell collection.

You may not qualify if…

• Complications with other active diseases, and difficult to assess patient response.
• Bacterial, fungal, or viral infection unable to control.
• Living with HIV.
• Active HBV and HCV infection.
• Pregnant and nursing mothers.
• Under systemic steroid use within a week of the treatment.
• Judged difficult to cooporate for continued evaluation.

Where it is running

• Shenzhen Geno-Immune Medical Institute — Shenzhen, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.